Read new research studies published in the Journal and presented at the ESMO Congress.

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Also Read: BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3 The analyst adds that the data for BNT327, including the ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

The latest edition of EMJ Oncology is out now, featuring coverage from the 2024 European Society for Medical Oncology ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

ECHO, a proprietary diagnostic for detection of ecDNA amplified oncogenes In September, analytical validation data was presented at the European Society for Medical Oncology (ESMO) Congress for the ...

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...